A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.

FDA approves new type of non-opioid pain medication in two decades - The new drug will be many times more expensive than a standard opioid option ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

It could help over 80 million Americans living with severe acute pain and reduce the effects of the opioid crisis.A new type of painkiller aimed at treating pain from an injury or surgery has been ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.